Kardiologiia,
Journal Year:
2023,
Volume and Issue:
63(10), P. 39 - 46
Published: Nov. 8, 2023
Aim.
To
evaluate
the
effect
of
inclisiran
therapy
on
parameters
lipid
metabolism
in
hospitalized
patients
with
acute
ischemic
stroke.
Material
and
methods.
A
prospective,
observational,
non-randomized
study
was
performed.
The
included
12
stroke
prescribed
a
combination
lipid-lowering
(284
mg
as
single
dose).
At
15
days
after
start
therapy,
changes
blood
composition
were
assessed.
For
quantitative
variables,
median,
maximum
minimum
values
determined.
significance
differences
between
related
samples
variables
assessed
using
Mann-Whitney
test.
Results.
Before
total
cholesterol
(TC)
7.33
mmol/l
low-density
lipoprotein
C
(LDL-C)
5.23
mmol/l.
TC
significantly
decreased
by
52.1
%
LDL-C
71.1
%.
proportion
who
reached
goal
66.7
There
no
adverse
events
considered
investigators
to
be
therapy.
Conclusion.
strategy
early
administration
(or
its
statin)
allows
safe
achievement
significant
reduction
already
Journal of Clinical Laboratory Analysis,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 14, 2025
Research
on
heart
injury
caused
by
COVID-19
is
limited
to
large
observational
and
retrospective
cohort
studies
using
imaging
or
pathological
data.
Reported
changes
in
the
levels
of
myocardial
markers
severe
diseases
have
been
limited,
with
few
mild
infections.
The
effects
cardiac
function
marker
not
yet
reported.
We
analyzed
data
from
outpatient
blood
samples
collected
at
Beijing
Anzhen
Hospital
during
2022
outbreak
used
same
periods
2020
2021
as
controls,
focusing
routine
tests,
coagulation,
markers,
other
indices
patients
palpitations.
number
palpitations
increased
4.87-fold
mass
2022.
damage
did
show
any
symptom-related
increases
but
decreased
within
normal
range.
proportion
whose
D-dimer
fibrinogen/fibrin
degradation
product
(FDP)
values
exceeded
reference
ranges
increased,
numbers
neutrophils,
monocytes,
platelets.
In
this
analysis,
we
found
little
change
COVID-19.
COVID-19,
attention
should
be
diverted
detecting
coagulation
test
results,
improve
circulation
prevent
thrombosis.
Clinical and Applied Thrombosis/Hemostasis,
Journal Year:
2025,
Volume and Issue:
31
Published: Jan. 1, 2025
Significant
progress
has
been
made
in
treating
Coronavirus
disease
(COVID)
–
an
infectious
caused
by
the
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2).
An
ominous
turn
pandemic
is
evolving
public
health
crisis
emanating
from
persistent
SARS-CoV-2
infection
and
its
associated
long-term
impact.
Long
COVID
or
post–COVID
describes
protean
symptoms
that
persist
at
least
3
months
after
onset
of
illness
last
for
individuals
with
a
history
confirmed
infection.
become
concern.
Millions
infected
are
now
facing
chronic
multi-organ
failures,
including
neuropsychiatric,
cardiovascular,
pulmonary,
kidney
complications.
In
general,
cause
long
unclear
but
factors
such
as
prolonged
activation
immune
responses,
viral
persistence
triggering
transcription
dysregulation
genes
normal
thrombotic
may
play
role
cardiovascular
Although
inflammatory
biomarkers
reported
other
disorders,
it
remains
whether
similar
manifestations
following
COVID.
Medications
sulodexide
directed
glycocalyx
coagulation
have
demonstrated
benefits
smaller
studies.
Here,
we
describe
outcomes
symposium
on
underlying
mechanisms
Journal of General Internal Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 25, 2025
Abstract
Background
Emerging
evidence
shows
the
lasting
impact
of
SARS-CoV-2
infection
on
health
care
use
and
needs.
Policy-makers
require
data
population-level
service
to
understand
patient
needs
system
impacts
following
hospitalization
for
COVID-19.
Objective
To
compare
within
12
months
COVID-19
among
people
with
without
pre-existing
disabilities,
determine
extent
which
such
is
related
disability
other
risk
factors.
Design
Population-based
cohort
study,
Ontario,
Canada.
Participants
Adults
disabilities
hospitalized
COVID-19,
01/25/2020–02/28/2022.
Main
Measures
We
used
Poisson
regression
model
adjusted
rate
ratios
(aRR)
ambulatory
visits,
diagnostic
testing,
emergency
department
(ED)
hospital
admissions,
palliative
visits
1-year
post-discharge,
comparing
patients
disabilities.
Models
were
sequentially
sociodemographic
factors,
comorbidities,
prior
use.
The
importance
each
set
covariates
in
its
ability
explain
observed
associations
was
determined
by
calculating
relative
changes
parameter
coefficients
after
sequential
risk-adjustment.
Key
Results
included
25,320
15,953
without.
In
year
had
higher
rates
tests,
ED
visits.
A
significant
proportion
these
explained
However,
associated
remained
elevated,
even
adjustment,
(aRR
1.09,
95%
CI
1.08,
1.10),
tests
1.14,
1.12,
1.16),
1.25,
1.21,
1.29),
admissions
1.16,
1.29).
Conclusions
These
findings
support
need
develop
evaluate
models
post-COVID-19
condition
that
address
Frontiers in Medicine,
Journal Year:
2024,
Volume and Issue:
11
Published: June 14, 2024
Long
COVID
is
a
condition
that
develops
in
subset
of
patients
after
COVID-19
infection
comprising
symptoms
varying
severity
encompassing
multiple
organ
systems.
Currently,
long
without
consensus
on
formal
definition,
identifiable
biomarkers,
and
validated
treatment.
expected
to
be
long-term
chronic
for
associated
with
suffering
incapacity.
There
an
urgent
need
clear
management
guidelines
the
primary
care
provider,
who
essential
bridging
gap
more
specialized
improve
quality
life
functionality
their
living
COVID.
The
purpose
this
mini
review
provide
providers
latest
highlights
from
existing
literature
regarding
most
common
current
recommendations.
This
also
underutilized
interventions
stellate
ganglion
blocks
low-dose
naltrexone,
both
well-established
safety
profiles
demonstrated
some
COVID,
encourages
prompt
referral
interventional
pain
management.
Sports Medicine and Health Science,
Journal Year:
2024,
Volume and Issue:
6(3), P. 221 - 231
Published: March 24, 2024
Cardiac
injury
and
sustained
cardiovascular
abnormalities
in
long-COVID
syndrome,
i.e.
post-acute
sequelae
of
coronavirus
disease
2019
(COVID-19)
have
emerged
as
a
debilitating
health
burden
that
has
posed
challenges
for
management
pre-existing
conditions
other
associated
chronic
comorbidities
the
most
vulnerable
group
patients
recovered
from
acute
COVID-19.
A
clear
evidence-based
guideline
treating
cardiac
issues
syndrome
is
still
lacking.
In
this
review,
we
summarized
common
symptoms
reported
months
after
COVID-19
illness
further
evaluated
possible
pathogenic
factors
underlying
pathophysiology
process
long-COVID.
The
mechanistic
understanding
how
Severe
Acute
Respiratory
Syndrome
Coronavirus
2
(SARS-CoV-2)
damages
heart
vasculatures
critical
developing
targeted
therapy
preventive
measures
limiting
viral
attacks.
Despite
currently
available
therapeutic
interventions,
considerable
portion
severe
reduced
functional
reserve
due
to
deconditioning.
Therefore,
rigorous
comprehensive
rehabilitation
program
with
individualized
exercise
protocols
would
be
instrumental
regain
physical
fitness
levels
comparable
their
pre-illness
baseline.
Journal of Osteopathic Medicine,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 17, 2024
In
2019,
emergence
of
the
novel
and
communicable
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infection
took
scientific
communities
by
surprise
imposed
significant
burden
on
healthcare
systems
globally.
Although
advent
this
disease
piqued
interest
academic
centers,
systems,
general
public,
there
is
still
much
yet
to
be
elucidated
regarding
epidemiology,
pathophysiology,
long-term
impacts
2019
(COVID-19).
It
has
been
established
that
long
COVID-19
can
impact
multiple
organ
including
cardiovascular
system,
unfavorably.
pathophysiology
damage
not
well
understood,
adverse
sequelae
may
range
from
chest
pain
arrhythmias
heart
failure
(HF),
myocardial
infarction,
or
sudden
cardiac
death.
For
any
postacute
patient
requiring
a
surgical
procedure,
potential
for
injury
secondary
must
considered
in
preoperative
examination.
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 11, 2024
ABSTRACT
Introduction
Long
COVID
affects
individuals’
labour
market
participation
in
many
ways.
While
some
cannot
work
at
all,
others
may
return
to
(RTW)
a
limited
capacity.
Determining
what
rehabilitation
or
related
strategies
are
safe
and
effective
for
facilitating
RTW
is
necessary.
Objectives
To
synthesize
evidence
on
interventions
people
living
with
identify
‘promising’
enhancing
ability
RTW.
Methods
We
followed
Arksey
&
O’Malley’s
methodology
the
PRISMA
extension
scoping
reviews.
Five
electronic
bibliographic
databases
grey
literature
were
searched.
The
included
various
study
designs,
such
as
randomized
controlled
trials
(RCT),
quasi-experimental
observational
studies.
Two
reviewers
conducted
screening
data
extraction,
disagreements
resolved
through
consensus.
Intervention
studies
categorized
promising
(statistically
significant
outcomes
≥
50%
RTW),
somewhat
(20%
<
not
(non-statistically
20%
RTW).
Results
Eleven
recommendations
eleven
intervention
identified.
Of
studies,
6
cohort
3
1
RCT
case
report.
Promising
multimodal
interdisciplinary
work-focused
(1
article),
psychoeducation,
pacing,
breathing
(2
articles),
shifting
focus
from
symptom
monitoring
optimizing
functional
enhanced
external
CounterPulsation
(EECP)
inflatable
pressure
improve
blood
flow
article).
Conclusion
Many
uncertainties
remain
regarding
which
optimal
characteristics
of
these
interventions.